India pharma products account for ~44% of the U.S. pharma market by volume and 47% of generics prescriptions. Thus, it would be difficult to replace Indian pharma manufacturers purely by a tariff increase. While US President Donald Trump is expected to make a detailed announcement on April 02, 2025, there is work-in-progress for a bilateral trade agreement.
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
We hosted Mr. Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance, and Ms. Archana Jatkar, Associate Secretary General, IPA, to understand the way forward for the Indian pharmaceutical industry after the announcement of tariffs on pharm imports by the US. Here are the key takeaways from this session:
The reciprocal tariffs would have a minimal impact on India pharma exports, as India has an export surplus of medicines to the US.
While US President Donald Trump is expected to make a detailed announcement on April 02, 2025, there is work-in-progress for a bilateral trade agreement.
The price erosion of 10-11% annually has already reduced the cost of medicines for the US patient pool. The impact of the tariffs, when implemented, would be passed on to patients, thereby increasing the cost of medicine.
Government of India has implemented schemes like PLI to promote indigenous manufacturing.
India pharma products account for ~44% of the U.S. pharma market by volume and 47% of generics prescriptions. Thus, it would be difficult to replace Indian pharma manufacturers purely by a tariff increase.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
